{
    "clinical_study": {
        "@rank": "35190", 
        "arm_group": [
            {
                "arm_group_label": "BF-200 ALA", 
                "arm_group_type": "Active Comparator", 
                "description": "Photodynamic therapy with BF-200 ALA"
            }, 
            {
                "arm_group_label": "Placebo to BF-200 ALA", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Photodynamic therapy with a nanoemulsion gel formulation similar to BF-200 ALA, but without the active ingredient 5-aminolevulinic acid."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of BF-200 ALA (Ameluz)\n      versus placebo in the field-directed treatment of mild to moderate actinic keratosis with\n      photodynamic therapy (PDT) when using the BF-RhodoLED lamp."
        }, 
        "brief_title": "Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis With Photodynamic Therapy", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females between 18 and 85 years of age (inclusive)\n\n          -  Presence of 4 to 8 clinically confirmed AK target lesions of mild to moderate\n             intensity within 1-2 fields\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity to 5-ALA or any ingredient of BF-200 ALA\n\n          -  Current treatment with immunosuppressive therapy\n\n          -  Presence of other malignant or benign tumors of the skin within the treatment area\n             (eg malignant melanoma, basal cell carcinoma [BCC] or squamous cell carcinoma [SCC])\n             within the last 4 weeks\n\n          -  Confirmed diagnosis of SCC for the representative lesion by screening biopsy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "87", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01966120", 
            "org_study_id": "ALA-AK-CT007", 
            "secondary_id": "2013-002510-12"
        }, 
        "intervention": {
            "arm_group_label": [
                "BF-200 ALA", 
                "Placebo to BF-200 ALA"
            ], 
            "intervention_name": "Photodynamic therapy", 
            "intervention_type": "Procedure", 
            "other_name": [
                "PDT", 
                "BF-RhodoLED"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Photodynamic Therapy", 
            "Field-directed Treatment"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bonn", 
                    "country": "Germany"
                }, 
                "name": "Dermatologisches Zentrum Bonn Friedensplatz"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Phase III, Multi-center Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz\u00ae) Versus Placebo in the Field-directed Treatment of Mild to Moderate Actinic Keratosis With Photodynamic Therapy (PDT) When Using the BF-RhodoLED\u00ae Lamp", 
        "overall_official": {
            "affiliation": "Dermatologisches Zentrum Bonn", 
            "last_name": "Uwe Reinhold, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complete responder rate at week 12 after last PDT", 
            "measure": "Patient complete response", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01966120"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Subject assessment of pain during PDT, lesion complete response, histopathological confirmed response rate", 
            "measure": "Safety and secondary efficacy parameters", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "source": "Biofrontera Bioscience GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biofrontera Bioscience GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}